CombiGene sails with tailwinds

Gene therapy company CombiGene is speedily progressing in its projects. The exclusive, global licensing agreement for its gene therapy candidate CG01 that was signed with pharmaceutical giant Spark Therapeutics last fall, was followed last week by the news that GMP production of CG01 has been made available for the final preclinical studies that precede the first in-human study. The company has now also signed an agreement with University of Michigan Medical School, regarding the lipodystrophy project CGT2. BioStock spoke to CEO Jan Nilsson to learn more.